THE US Food and Drug
Administration has this month
approved Fulyzaq (crofelemer) for
the relief of symptoms caused by
diarrhea in HIV/AIDS patients taking
antiretroviral therapy.
The drug is derived from the red
sap of the Croton lechleri plant, and
is the second botanical prescription
drug approved by FDA (after Veregen
(sinecatechins), a treatment for
external genital and perianal warts,
was approved in 2006).
Fulyzaq is intended to be used in
HIV/AIDS patients whose diarrhea is
not caused by an infection from a
virus, bacteria, or parasite.
As such, patients are required to
take Fulyzaq two times a day to
manage watery diarrhea due to the
secretion of electrolytes and water
in the gastrointestinal tract.The above article was sent to subscribers in Pharmacy Daily's issue from 09 Jan 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Jan 13
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.